{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 15,
  "pageCount": 33,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide outlines a two-part study structure involving screening, randomization, a double-blind treatment period, and an open-label maintenance period.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/15",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.78,
        "x": 0.12,
        "y": 0.17
      },
      "kind": "diagram",
      "text": "Clinical trial flow diagram showing Part 1 and Part 2, randomization, treatment arms, and measurement points.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "261f7c5f-6ead-47e8-88d4-129138d197bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.075
      },
      "kind": "list",
      "text": "Primary endpoint: Annualized change in eGFR from baseline to follow-up in Part 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a8954eb-9e54-44c2-b676-f18c5a82cd64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "list",
      "text": "Key secondary endpoints: Incidence of serum ALT levels >3 x ULN; Annualized change in eGFR in Part 2; Annualized rate of change in eGFR in Part 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eff6c4ba-ae9b-4d00-ab27-2edc09b70ae3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Lixivaptan: Phase 3 Pivotal Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce1b95bc-3541-4302-bcf1-c9633e0abf76",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7d3782a7-5798-4fed-b710-e6558a91e47c",
      "evidence": "list/bullet: Key secondary endpoints: Incidence of serum ALT levels >3 x ULN...",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 11,
      "beatId": "858c031e-6b1f-41e5-b1d3-a2219b0e9631",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides data on the market potential of the company's treatments",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}